article thumbnail

SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]

Annals of Family Medicine

Context Two thirds of diabetes patients complicated with hypertension, and comorbidity increase 4-fold risk of atherosclerotic cardiovascular disease (ASCVD). Setting or Dataset Five electronic systems of community clinic. Population Studied individuals with comorbidity of hypertension and type 2 diabetes.

article thumbnail

DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes

Physician's Weekly

WEDNESDAY, June 18, 2025 (HealthDay News) — The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes, according to a study published online June 9 in JAMA Internal Medicine. Pilla, M.D., Pilla, M.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Key Facts GPs Should Know About GLP-1 Analogs

Family Medicine Initiative

Yes, one year after stopping the medication, patients regain ½ – ⅔ of their previous weight loss: What are other clinical benefits? Cardiovascular Events The SELECT trial 1 randomized 17,604 patients with preexisting CVD and overweight/obesity. over 40 months (ARR). semaglutide 2.4 mg or placebo for 52 weeks. semaglutide 1.0

Diabetes 130
article thumbnail

ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes

Physician's Weekly

from the Velocity Clinical Research Center at Medical City Dallas, and colleagues conducted a phase 3 trial involving participants with type 2 diabetes treated only with diet and exercise, an HbA1c level of ≥7.0 Mild-to-moderate gastrointestinal events were the most common adverse events with orforglipron.

article thumbnail

What to Expect at the ADA 85th Scientific Sessions: Obesity, Nutrition, Prevention, and More

Physician's Weekly

The ADA’s 85th Scientific Sessions will highlight breakthroughs in obesity and diabetes care, including GLP-1 therapies, tech advances, and prevention tools. The event will convene more than 11,000 global researchers, clinicians, and industry leaders to highlight major strides in research and real-world treatment. Roughly 42% (109.9

article thumbnail

Why Identifying and Managing Giant Cell Arteritis as an Emergency Is Crucial

Physician's Weekly

I’m the Vice Chairman of Rheumatology at the Cleveland Clinic and the co-director of the Center for Vasculitis Care and Research. And I’m here today to talk about giant cell arteritis in clinical practice. So always important to consider the clinical context and patient symptoms there. Hello everyone.

article thumbnail

Why I don’t do “weight loss” as a primary care physician

Vida Family Medicine

From specialized obesity clinics to online services offering quick prescriptions, the options can feel overwhelming. While losing weight is often suggested to lower the risk of chronic conditions like diabetes, high blood pressure, or heart disease, the risk of prescribing weight loss is overlooked.